Addition of Levetiracetam May Improve Survival for Glioblastoma
the Cancer Therapy Advisor take:
Levetiracetam may provide a survival benefit in patients with glioblastoma who receive temozolomide-based chemotherapy, a recent study published online in the journal Cancer has shown.
For the study, researchers identified 103 patients with primary glioblastoma who received comcomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide. Of those, 56% received levetiracetam during temozolomide chemotherapy for at least 3 months.
Results showed that median progression-free survival was 9.4 months (95% CI: 7.5-11.3) among those who took levetiracetam compared with 6.7 months (95% CI: 5.8-7.6) among those who did not receive the drug (P = 0.010). Median overall survival was 25.7 (95% CI: 21.7-29.7) and 16.7 months (95% CI: 12.1-21.3), respectively (P = 0.027).
The findings suggest that levetiracetam may improve survival in this patient population, but the authors note that a randomized study is warranted.
Previous studies have suggested the chemosensitizing effect of levetiracetam, an antiepileptic drug, but data surrounding survival benefit is lacking.
Levetiracetam may provide a survival benefit in patients with glioblastoma who receive temozolomide-based chemotherapy.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Pazopanib Plus Cetuximab May Be Effective and Well-Tolerated in Head and Neck Cancer
- FDA Approves Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
- Aggressive Follow-Up Imaging in Breast Cancer Is Geography-Specific
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Non-Small Cell Lung Cancer (NSCLC) Drug Treatments